EMA Recommends Granting a Marketing Authorisation for Ensartinib By Ogkologos - October 9, 2026 8 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of adult patients with ALK-positive, advanced NSCLC Source RELATED ARTICLESMORE FROM AUTHOR Taking on the RAS Challenge Adjuvant fractionated radiotherapy significantly improves DFS in patients with atypical meningioma who have undergone complete surgical resection ESMO Calls for the European Commission to Propose an EU Directive on Psychosocial Risks (PSR) at Work to Protect the Oncology Workforce MOST POPULAR FDA Approves Palbociclib with Trastuzumab, With or Without Pertuzumab, and Endocrine... July 29, 2026 Cancer Patients Have Been Lonelier During the COVID-19 Pandemic May 27, 2021 Darolutamide in Combination with ADT and Docetaxel Increases Overall Survival in... February 27, 2023 Breast Cancer Survivor Driven from Her Home by Noxious Gases from... June 11, 2021 Load more HOT NEWS Teacher’s Mental Health Check-In Board Goes Viral For The ‘Beautiful’ Standard... 6 things you need to know about cervical screening FDA Approves Liquid Biopsy NGS Companion Diagnostic Test for Multiple Cancers... Ifosfamide May Be Treatment of Choice for Some People with Ewing...
